Formulation & Device Lifecycle Management

3/13/2019 08:55 - 09:30

Globally, the pressure on healthcare costs and resources is increasing and aspects such as limited infusion capacity or complex drug preparation procedures markedly contribute to this challenging situation. Especially with a large number of biologic agents being developed for intravenous infusion and frequently for combination therapy, companies are more and more looking into simplifying drug delivery with the aim to improve access and to reduce healthcare costs and resources. Today, subcutaneous versions are available for a number of biotherapeutics even in oncology there is the desire to explore whether these presentations can be administered in the home setting. Typically, in case a treatment is well tolerated, given in monotherapy, and patients live far from an oncology center, such a flexible care setting would be appreciated in a number of countries. A key requisite for enabling home- or self-administration would be the availability of a suitable injection device that can administer larger dosing volumes exceeding 5 mL or more (i.e., ideally ready-to-use with limited administration steps required). In addition, connected device features, such as dosing reminders, adherence trackers, and electronic patient diaries, that also allow an ongoing dialogue with healthcare professionals can be of value in this context. The keynote presentation will present an update of the current status in the field, discuss related opportunities and challenges, and outline future perspectives.